华氏巨球蛋白血症的诊断与治疗  

Diagnosis and treatment of Waldenstrom's macroglobulinemia

作　　者：李健平 于文征[1] Li Jianping;Yu Wenzheng(Department of Hematology,Hospital Affiliated to Binzhou Medical College,Binzhou 256600,China)

机构地区：[1]滨州医学院附属医院血液内科,滨州256600

出　　处：《国际医药卫生导报》2022年第10期1476-1480,共5页International Medicine and Health Guidance News

摘　　要：华氏巨球蛋白血症(WM)是一类少见的惰性非霍奇金淋巴瘤,以免疫球蛋白M型单克隆免疫球蛋白和淋巴浆细胞浸润为主要特征。多数患者治疗后仍不能达到完全缓解,所以也被认为是一种不可治愈的疾病。近年来,随着对WM发病机制的深入研究及免疫学、分子生物学的发展,新型靶向药物的研发不断取得成果,为WM患者的治疗提供了新的治疗靶点及方案,临床预后得到了显著改善。本文对WM的诊断与治疗进展进行相关综述。Waldenstrom's macroglobulinemia(WM)is a rare type of indolent non-Hodgkin's lymphoma,which is mainly characterized by immunoglobulin M type monoclonal immunoglobulin and lymphoplasmic cell infiltration.Most patients can not achieve complete remission(CR)after treatment,so it is considered to be an incurable disease.In recent years,with the in-depth research on WM pathogenesis and the development of immunology and molecular biology,the new achievements have been made in the research and development of new targeted drugs,and all of them have provided new therapeutic targets and schemes for the treatment of WM patients,which has significantly improved the clinical prognosis.We reviewed the diagnosis and treatment of WM.

关 键 词：华氏巨球蛋白血症 BTK抑制剂 蛋白酶体抑制剂 治疗 

分 类 号：R733.1[医药卫生—肿瘤]